The Diagnostic value of FibroScan for the degree of liver fibrosis in patients with ALT<2×ULN chronic hepatitis B
Article Sidebar
Main Article Content
Abstract
Objective: This paper studied the diagnostic value of FibroScan (FS) for the degree of liver fibrosis in patients with ALT<2×ULN chronic hepatitis B(CHB).
Methods: 100 ALT<2×ULN CHB patients, who also with liver biopsy in our hospital from January 2017 to May 2019 were enrolled. According to the results of liver biopsy, patients that below G2 were classified as mild inflammation group. patients that above G2 were classified as moderate inflammation group; patients that below S2 were designated as non-significant fibrosis group, patients that above S2 and equal to S2 were designated as significant fibrosis group, then compared it with the results of Liver Stiffness Measurement (LSM) which measured by FS respectively.
Results: 91 out of 100 patients had complete data, there were 60 patients in mild liver inflammation group, 31 in the moderate inflammation group, 53 patients belong to no significant fibrosis group and 17 patients belong to significant fibrosis group, comparison, there were statistically significant between the two groups of LSM (Z= 3.303, P = 0.001; Z= 4.944, P < 0.001); FS diagnosis of significant liver fibrosis area under the curve (ACU) were 0.851, 95% CI (0.765-0.937), when the Yoden index is 0.59, the LSM optimal cut-off value is 5.35, and the corresponding sensitivity value is 86.4%, the specificity value is 72.5%.
Conclusion: For patients with ALT<2×ULN CHB, the liver stiffness measurement (LSM) measured by FS is related to the degree of fibrosis in the liver tissue. When the optimal cut-off value of LSM is 5.35, its diagnosis is most effective in significant liver fibrosis.
Downloads
Article Details
Copyright (c) 2020 Shi W, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Matthews K, MacGilchrist A, Coulter-Smith M, Jones J, Cetnarskyj R (2019) A nurse-led FibroScan((R)) outreach clinic encourages socially deprived heavy drinkers to engage with liver services. J Clin Nurs 28: 650-662. Link: https://bit.ly/3fTMvhG
Scott DR, Levy MT (2010) Liver transient elastography (Fibroscan): a place in the management algorithms of chronic viral hepatitis. Antivir Ther 15: 1-11 . Link: https://bit.ly/3cDkIQu
Liu X, Kang J, Wang H, Huang T, Li C (2018) Construction of Fluorescein Isothiocyanate-Labeled MSNs/PEG/Lycorine/Antibody as Drug Carrier for Targeting Prostate Cancer Cells. J Nanosci Nanotechnol 18: 4471-4477 . Link: https://bit.ly/362VAjq
Jia J, Hou J, Ding H, Chen G, Xie Q, et al. (2015) Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 30: 756-762 . Link: https://bit.ly/2Z6AlvE
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, et al. (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381: 468-475 . Link: https://bit.ly/2Tcy8et
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, et al. (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52: 886-893 . Link: https://bit.ly/2X0aQcW
Dong XQ, Wu Z, Zhao H, Wang GQ, China HepB-Related Fibrosis Assessment Research Group (2019) Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat 26: 297-307 . Link: https://bit.ly/2Z8dZdj
Lu W, Zhang YP, Zhu HG, Zhang T, Zhang L, et al. (2019) Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection. Br J Biomed Sci 76: 137-142 . Link: https://bit.ly/3cxUuia
Andruszkow J, Hartleben B, Schlué J, Ritz T, Knüchel R, et al. (2019) [Staging of liver fibrosis in biliary atresia : Comparison of Chevallier and Ishak score as well as automated evaluation. Pathologe 40: 85-92 . Link: https://bit.ly/2TabNyd
Shaheen AA, Wan AF, Myers RP (2007) FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 102: 2589-2600 . Link: https://bit.ly/2X532qt
Xia S, Ren X, Ni Z, Zhan W (2019) A Noninvasive Method-Shear-Wave Elastography Compared With Transient Elastography in Evaluation of Liver Fibrosis in Patients With Chronic Hepatitis B. Ultrasound Q 35: 147-152 . Link: https://bit.ly/2LAd3q2
Chon YE, Choi EH, Song KJ, Park JY, Kim DY, et al. (2012) Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 7: e44930 . Link: https://bit.ly/2z1kiop
Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, et al. (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51: 828-835 . Link: https://bit.ly/2Z6ZYwn
Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, et al. (2013) Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 58: 65-72 . Link: https://bit.ly/2TcPNTc
Xie QX, Xu N, Jiang XP, Zhang YF, Zhang ZH, et al. (2016) Role of FibroScan in liver fibrosis evaluation in patients with chronic hepatitis B virus infection and related influencing factors. Zhonghua Gan Zang Bing Za Zhi 24: 659-664 . Link: https://bit.ly/2LvTjnp
Bae RC, Cho HJ, Oh JT, Lee EK, Heo J, et al. (2010) Clinical factors influencing liver stiffness as measured by transient elastography (Fibroscan) in patients with chronic liver disease. Korean J Hepatol 16: 123-130. Link: https://bit.ly/2Z6DWKk